Guardant Health, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter ended September 30, 2026, disclosing revenue of $360,975 thousand and a net loss of $124,362 thousand for the three-month period.

Key Highlights

  • Quarterly revenue of $360,975 thousand for the three months ended September 30, 2026, compared to $265,196 thousand for the same period in 2025, according to the filing.
  • Net loss of $124,362 thousand for Q3 2026, versus a net loss of $92,725 thousand in Q3 2025, as reported in the condensed consolidated statements of operations.
  • Nine-month revenue of $997,618 thousand for the period ended September 30, 2026, up from $700,755 thousand in the same period of 2025.
  • Net loss per share, basic and diluted, of $(0.93) for Q3 2026, compared to $(0.74) in Q3 2025, based on weighted-average shares of 134,422 thousand.
  • Total assets of $1,885,642 thousand as of September 30, 2026, down from $2,013,659 thousand as of December 31, 2025.
  • Accumulated deficit of $3,351,091 thousand as of September 30, 2026, compared to $2,994,512 thousand as of December 31, 2025.
  • 135,285,975 shares of common stock outstanding as of October 30, 2026, per the filing's cover page.

Guardant Health Financial Results for the Quarter Ended September 30, 2026

Guardant Health, Inc. (NASDAQ:GH), a Delaware corporation headquartered in Palo Alto, California, reported quarterly revenue of $360,975 thousand for the three months ended September 30, 2026, according to the unaudited condensed consolidated statements of operations included in the filing. Total costs and operating expenses for the same quarter were $493,740 thousand, resulting in a loss from operations of $132,765 thousand. For the nine months ended September 30, 2026, the company disclosed revenue of $997,618 thousand against total operating costs of $1,380,851 thousand, producing a nine-month loss from operations of $383,233 thousand.

The filing disclosed that cost of revenue for Q3 2026 was $124,822 thousand, research and development expense was $100,838 thousand, sales and marketing expense was $177,218 thousand, and general and administrative expense was $90,862 thousand. Interest income for the quarter was $9,749 thousand, partially offsetting interest expense of $1,345 thousand. After a provision for income taxes of $343 thousand, the company reported a net loss of $124,362 thousand for Q3 2026, or $(0.93) per share on a basic and diluted basis.

As of September 30, 2026, the company's balance sheet reflected total assets of $1,885,642 thousand and total liabilities of $2,161,544 thousand, including convertible senior notes, net, of $1,502,413 thousand. Cash and cash equivalents stood at $1,026,848 thousand, compared to $378,203 thousand as of December 31, 2025. Short-term marketable securities, which were $823,395 thousand at year-end 2025, were reported at zero as of September 30, 2026. Total stockholders' deficit was $(275,902) thousand as of September 30, 2026. The company noted forward-looking statements in the filing are subject to risks and uncertainties and are the company's own projections as of the filing date.

What Was Disclosed

Guardant Health filed its Form 10-Q for the quarter ended September 30, 2026, disclosing unaudited financial results including revenue, operating losses, balance sheet data, and share counts for both the three-month and nine-month periods, with 134,719,874 shares issued and outstanding as of September 30, 2026.